Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,218 USD | +3,15% | +1,87% | -82,83% |
30/04 | Transcript : CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call | |
23/04 | Transcript : CNS Pharmaceuticals, Inc. - Special Call |
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 6,67 mln. 6,22 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -15 mln. -13,99 mln. | Nettowinst (verlies) 2023 | -18 mln. -16,79 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 9,65 mln. 9 mln. | Nettoliquiditeiten 2023 | 248K 231K | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-0,21
x | K/w-verhouding 2023 |
-0,25
x | Werknemers | 4 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 90,47% |
Recentste transcriptie over CNS Pharmaceuticals, Inc.
1 dag | +3,15% | ||
1 week | +1,87% | ||
Lopende maand | +3,12% | ||
1 maand | -39,41% | ||
3 maanden | -13,66% | ||
6 maanden | -89,05% | ||
Lopend jaar | -82,83% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Climaco
CEO | Chief Executive Officer | 55 | 01-09-17 |
Director of Finance/CFO | 45 | 13-11-19 | |
Sandra Silberman
CTO | Chief Tech/Sci/R&D Officer | 69 | 01-12-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Donald Picker
CTO | Chief Tech/Sci/R&D Officer | 78 | 01-01-18 |
John Climaco
CEO | Chief Executive Officer | 55 | 01-09-17 |
Faith Charles
CHM | Chairman | 62 | 03-01-23 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
01-05-24 | 0,218 | +3,15% | 73 723 |
30-04-24 | 0,2114 | -1,70% | 48 240 |
29-04-24 | 0,215 | 0,00% | 67 136 |
26-04-24 | 0,215 | +5,39% | 109 097 |
25-04-24 | 0,204 | -4,67% | 105 007 |
uitgestelde koers Nasdaq, 01 mei 2024 om 22:00 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-82,83% | 2,32 mln. | |
+0,67% | 42,4 mld. | |
+44,30% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+6,55% | 24,94 mld. | |
-21,66% | 18,96 mld. | |
+29,96% | 12,3 mld. | |
-1,57% | 11,95 mld. | |
+16,03% | 11,32 mld. | |
-4,80% | 11,55 mld. |